LIME Study (LFB IVIg MMN Efficacy Study)

Inclusion Criteria:

1. Male or female patient aged 18 to 80 years.

2. Written informed consent obtained prior to any study-related procedures.

3. Diagnosis of definite or probable MMN according to the EFNS/PNS Guideline 2010, Firstrevision made by neuromuscular disease specialists with specific electrodiagnosticexpertise.

4. Patients treated with a stable maintenance dose within 15% of any brand of IVIg (Kiovig® excluded) at 1 g/kg for 1-3 days up to 2 g/Kg for 2-5 days every 4 to 8 weeks (+/- 7 days), according to the EFNS/PNS Guideline 2010, First revision for at least 3months prior to enrolment.

5. Covered by national health care insurance system if required by local regulations.

Exclusion Criteria:

1. Upper motor neuron, bulbar, cranial nerve or significant sensory deficit.

2. CSF protein >100 mg/dL (if available and done as part of a previous evaluation).

3. Any other ongoing disease that may cause neuropathy, such as toxin exposure, dietarydifficency, uncontrolled diabetes, hyperthyroidism, cancer, systemic lupuserythematosus or other connective diseases, infection with HIV, hepatitis B virus (HBV), or hepatitis C (HCV), Lyme disease, multiple myeloma, Waldenström'smacroglobulinemia, amyloid, and hereditary neuropathy.

4. BMI >= 40 kg/m2.

5. Known hypersensitivity to the active substance or to any of the excipients of I10E (glycine and polysorbate 80) or Kiovig(glycine).

6. Patient who have been treated with Kiovig shall not have received Kiovig during thelast 6 months prior to enrolment.

7. History of IgA deficiency, except if the absence of anti-IgA antibodies is documented.

8. Protein-losing enteropathy characterised by serum protein levels <60 g/l and serumalbumin levels <30 g/l or nephrotic syndrome characterised by proteinuria >=3.5 g/24hours, serum protein levels <60 g/l and serum albumin levels <30 g/l.

9. History of cardiac insufficiency (New York Heart Association (NYHA) III/IV),uncontrolled cardiac arrythmia, unstable ischemic heart disease, or uncontrolledhypertension.

10. History of venous thrombo-embolic disease, myocardial infarction, or cerebrovascularaccident.

11. Risk factor for blood hyperviscosity such as cryoglobulinemia or haematologicalmalignancy with monoclonal gammopathy.

12. Glomerular filtration rate <80 ml/min/1.73m2 measured according to the Modified Dietin Renal Disease (MDRD) calculation.

13. Serum levels of AST, ALT >2 times upper limit of normal range.

14. Treatment within 12 months prior to screeening with immunomodulator orimmunosuppressant agent (including but not limited to cyclophosphamide, cyclosporine,interferon-a, interferon-b 1a, anti-CD20, alemtuzumab, azathioprine, etanarcept,mycophenolate mofetil, methotrexate, haematopoietic stem cell transplantation).

15. Administration of another investigational product within the last month prior toinclusion.

16. Plasma exchange, blood products or derivatives administered with the last 3 monthsprior to screening.

17. Woman with positive results of pregnancy test or breast-feeding woman or woman ofchildbearing potential without an effective contraception. Effective contraception are injectible, patch or combined oestro-progestative orprogestative contraceptives, Cooper T or levonorgest releasing intra-uterine devices,depot intramuscular medroxyprogesterone, subcutaneous progestative contraceptiveimplants, condoms or occlusive caps (diaphragm or cervical/vault caps) withspermicide, true abstinence (when this is in line with the preferred and usuallifestyle of the patient).

18. Any serious medical condition that would interfere with the clinical assessment ofI10E or prevent the patient from complying with the protocol requirements.

19. Anticipated poor compliance of patient with study procedures during the 12 monthduration of the study.

20. Drug or alcohol abuse.